

PERFORMANCE IN DELIVERING RESEARCH AT YEovil HOSPITAL

Name of Trial	REC Ref Number	IRAS No	Target No of patients agreed	Minimum No of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Recruitment target date agreed	Date agreed to recruit the target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date trial closed to recruitment	Reason for closure
An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who	16/LO/0779	203698	Number agreed	1	1	Date Agreed	20/03/2017	1	1	13/06/2017	Recruitment Finished
Safety and efficacy of opicapone in clinical practice in Parkinson's disease with wearing-off motor fluctuations	16/EE/0357	206501	Number agreed	5	5	Date Agreed	31/12/2017	6	6	13/12/2017	Recruitment Finished

Author: Joanna Allison (Clinical Research Manager) / Nicky Marks (Research Facilitator)

Review Date 30/04/2018